GeoVax Labs and ViaMune have signed a co-development agreement for cancer immunotherapy programmes.

The former is a biotechnology company, whereas the latter is a clinical-stage biotechnology company and both are based in the US.

Chinese-based biopharmaceutical company Yisheng Biopharma has announced a collaboration with US-based non-profit organisation The Scripps Research Institute (TSRI), which is focused on research in biomedical sciences.

The collaboration will be aimed at testing a new generation of AIDS vaccine based on trimmers and self-assembling nano particles designed by TSRI’s scientists and a technology developed by Yisheng Biopharma.

"The collaboration is expected to result in the development of more effective and safe vaccines against HIV."

The collaboration is expected to result in the development of more effective and safe vaccines against HIV.

Spanish biopharmaceutical company Oryzon Genomics has raised €0.6m ($0.67m) through the private placement of 175,071 shares of its common stock.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Priced at €3.43 ($3.82) a share, the placement was subscribed to by US-based Alzheimer’s Drug Discovery Foundation.

German-based Axiogenesis biotechnology company has signed an agreement with UK-based contract research organisation Metrion Biosciences.

As part of the agreement, the former will share its recently developed iPS-derived cardiomyocytes and neurons with Metrion Biosciences, which will profile and validate them using its high-quality screening platforms.

The commercial cell products will also be used in Metrion’s optimised ion channel screening, cardiac safety and translational phenotypic assays.

The agreement is expected to result in the development of human iPSC-derived cardiomyocytes and neurons for translational drug discovery.